
Functional Vectors for Treatment of MesotheliomaAward last edited on: 1/15/2009
Sponsored Program
SBIRAwarding Agency
NIH : NCITotal Award Amount
$165,920Award Phase
1Solicitation Topic Code
395Principal Investigator
Natalia BalabaiCompany Information
Phase I
Contract Number: 1R43CA128278-01A1Start Date: 9/1/2008 Completed: 8/31/2010
Phase I year
2008Phase I Amount
$165,920Project narrative:
Patients with Malignant Pleural Mesothelioma (MPM) confront a dismal prognosis. The median survival of patients with mesothelioma is 9-12 months, with extremely low long-term survival over five years regardless of treatment modality. With the use of combination chemotherapy consisting of cisplatin and pemetrexed, the median survival rate is increased by 3-4 months; Most patients are not viable candidates for surgical intervention, and those that elect to have surgery experience mainly palliative benefits. Despite recent advances in surgery, radiotherapy, and chemotherapy, there is no reliably curative treatment for MPM and long-term patient survival is rarely realized. We propose to develop a charge-reversal amphiphile as carrier of genetic material for mesothelioma cancer cells, which may offer the best long-term solution for adults combating this cancer.
Public Health Relevance:
This Public Health Relevance is not available.
Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00